The START Center for Cancer Research (START), the world’s largest community-based network of clinical trial sites specialising in early-phase oncology trials, has announced a strategic partnership with Trialing, a platform dedicated to connecting physicians and patients to clinical trials, helping physicians rapidly identify, evaluate, and refer patients to appropriate studies.
Through this exclusive collaboration, START will work with Trialing across Europe to distribute curated information on active oncology clinical trials, share real-time study updates, and notify medical oncologists when enrolment slots become available through Trialing’s physician network. The partnership is designed to streamline referrals, improve awareness of trial opportunities, and ultimately expand patient access to innovative cancer therapies.
‘Access remains one of the greatest barriers in oncology clinical research,’ said Nick Slack, MBE, Chairman and CEO of START. ‘Partnering with Trialing allows us to engage physicians on a platform they already know and trust, provide clear and timely visibility into our hundreds of active trials, and make it easier to connect patients with START’s clinical trial sites across Europe. By reducing friction in the referral process and increasing physician awareness of START, we advance our mission of delivering hope through access.’
Trialing leverages innovative technology, accurate data, and an agile, physician-focused approach supported by its internal medical team to revolutionize how clinical trials are accessed. By connecting physicians, patients, and the pharmaceutical industry through a single platform, Trialing enables faster identification of appropriate studies through structured clinical decision pathways and reduces barriers to trial participation.
START’s European network of clinical trial sites continues to grow, with a strong focus on accelerating early-phase trials while maintaining deep relationships with referring physicians and community oncologists. The collaboration with Trialing supports START’s mission to bring innovative research closer to patients by improving transparency, communication, and referral pathways.
Trialing’s platform will enable START to provide dynamic study updates, ensuring physicians have current information on eligibility criteria and enrollment status, a key factor in reducing delays and missed referral opportunities.
This partnership reflects a shared vision to modernise clinical trial access, strengthen physician engagement, and accelerate oncology research across Europe.
